Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.

An updated analysis of IMvigor010 reported overall survival by ctDNA status for adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. The abstract does not name the assay.

European UrologyPubMed 37500339DOI 10.1016/j.eururo.2023.06.007